A Partnership Built to Succeed

By joining forces, Public Health Vaccines, LLC and Crozet BioPharma, LLC are applying their collective vaccine expertise to build a safe and effective novel vaccine against Nipah virus disease, with funding from CEPI.

Our goal is to develop a single-dose Nipah vaccine that is well-tolerated and effective by employing novel technologies and product development strategies to address this major unmet public health need. In the World Health Organization R&D Blueprint, Nipah has been named a priority diseases for fast track vaccine development.

Public Health Vaccines, LLC

Crozet BioPharma


Nipah by the Numbers

Frequently Asked Questions

Check out our FAQ page for answers to the most frequently asked questions about the Nipah virus and our vaccine project.


A Novel Vaccine Development Method

The Nipah vaccine being developed by PHV and Crozet uses recombinant DNA technology. Like many of the most successful vaccines used to protect against infectious diseases (e.g. measles, mumps, German measles, chickenpox, smallpox, oral polio, rotavirus, yellow fever), the recombinant vaccine against Nipah is a live, replication competent vaccine, engineered to balance safety and effectiveness.

Latest News

March 23, 2023

NPR Series Examines Nipah Transmission

The new NPR series "Hidden Viruses: How Pandemics Really Begin" examines how disease are increasingly crossing from animals to humans.
April 23, 2021

The Next Pandemic” Nipah virus?

GAVI, the vaccine alliance, examines the possibility of the Nipah virus causing another pandemic someday.  The major concern is that Nipah virus is  so deadly with […]
April 1, 2021

CEPI launches plan to tackle risk of future pandemics and epidemics

The Coalition for Epidemic Preparedness or CEPI has launched a US $3.5 bn plan to fight pandemics and epidemics.  CEPI plans a 3-prong approach built on […]
One Health Initiative